Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Abstract

Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14–1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25–1.30]). Conclusions In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable.

Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review

“…This may be particularly the case when considering respiratory support strategies, which are dependent on ICU capacity, availability of advanced respiratory support, and ICU admission criteria (e.g. age, comorbidities) [ 71 ].…”

Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19

“…10 We undertook an analysis of observational data from the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC). [11][12][13][14] The main objective of this cohort study was to compare variations over time and across WHO regions of corticosteroid use for severe COVID-19. The first secondary objective was to evaluate the association between publication of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial 15 and of the WHO guidelines 2 and the temporal trends in corticosteroid use by region.…”

“…We undertook an analysis of observational data from the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) . The main objective of this cohort study was to compare variations over time and across WHO regions of corticosteroid use for severe COVID-19.…”

Respiratory support before venovenous ECMO for COVID-19: what is the price?

“…Several questions remain regarding the prognostic role of spontaneous breathing, non-invasive, and mechanical ventilation before ECMO. For example, how to weight the effect of duration and method 10 of non-invasive respiratory support, how to quantify the risk of patient self-inflicted lung injury, and whether a threshold of time and intensity of ventilation before ECMO cannulation might not be protective with regards to survival remain unclear. Future studies are expected to shed light on these questions.…”